Tarsus Pharmaceuticals Earnings Call Transcripts
Fiscal Year 2026
-
XDEMVY's launch has exceeded expectations, with rapid revenue growth, broad payer coverage, and strong prescriber engagement. The addressable market remains largely untapped, and DTC campaigns are expanding awareness. Peak sales guidance has doubled to $2B+, with a robust pipeline and strong financials supporting future growth.
-
The company is rapidly expanding in eye care, with XDEMVY achieving $450M in year-two revenue and targeting $2B+ peak sales. Pipeline assets TP-04 and TP-05 address large unmet needs, with key data readouts expected in 2027. DTC efforts and broad payer coverage are fueling growth.
Fiscal Year 2025
-
Full-year 2025 net sales reached $451.4 million, with XDEMVY now profitable and US peak sales potential raised to over $2 billion. 2026 guidance projects 50%+ revenue growth, strong gross margins, and continued pipeline expansion, supported by robust prescriber and patient demand.
-
Strong Q3 results and robust revenue guidance reflect effective commercial execution and DTC strategy. Pipeline progress includes a phase II ocular rosacea study starting by year-end and a Lyme disease prophylactic advancing toward partnership.
-
Q3 2025 saw exceptional growth, with XDEMVY achieving $119M in net sales and over 103,000 bottles dispensed, driven by strong physician adoption and DTC efforts. Guidance for Q4 and 2025 remains robust, with continued expansion in pipeline and international markets.
-
XDEMVY continues robust growth with strong prescriber engagement, high insurance coverage, and effective DTC campaigns. Expansion efforts focus on increasing prescribing depth, retreatment rates, and international markets, while pipeline assets in ocular rosacea and Lyme disease prevention advance toward clinical milestones.
-
Record Q2 net sales of $102.7M and 91,000 bottles dispensed highlight XDEMVY's rapid adoption, driven by DTC campaigns and broad access. Guidance calls for continued growth, with a robust pipeline and expanding prescriber base supporting long-term potential.
-
XDEMVY's launch has driven strong sequential growth, aided by an expanded sales force and early payer coverage. Prescribing is broadening across multiple eye care categories, with significant market potential remaining. Pipeline programs in ocular rosacea and Lyme disease are advancing, and international expansion is underway.
-
XDEMVY continues to drive strong revenue growth, with expanding adoption among eye care professionals and a robust sales force. Pipeline programs in ocular rosacea and Lyme disease offer significant future opportunities, while international expansion and business development are underway.
-
XDEMVY's launch has exceeded expectations, driven by strong prescriber education, broad payer coverage, and expanding sales force efficiency. Growth is supported by direct-to-consumer campaigns and new market opportunities, with a robust pipeline targeting ocular rosacea and Lyme disease.
-
XDEMVY’s launch has driven strong demand, broad payer coverage, and rapid physician adoption, with a focus on expanding within a 9 million patient segment and deepening engagement among 15,000 key prescribers. Pipeline assets target ocular rosacea and Lyme disease, supported by robust financial resources.
-
XDEMVY's launch has exceeded expectations, with strong sales, broad payer coverage, and ongoing market education driving growth. International expansion and a robust pipeline targeting ocular rosacea and Lyme disease are underway, supported by a strong cash position.
-
XDEMVY's launch has surpassed expectations, with strong revenue growth, broadening prescriber adoption, and over 90% payer coverage. Pipeline development continues with ocular rosacea and Lyme disease programs, while DTC and Salesforce expansion are set to drive further growth.
-
Q1 2025 delivered $78M in XDEMVY sales, up 217% year-over-year, driven by expanded sales force, broad payer coverage, and impactful DTC campaigns. Strong financial position with $408M in cash supports continued growth and pipeline advancement.
-
XDEMVY achieved strong initial sales and broad coverage, with significant market potential remaining. The company is advancing a gel-based ocular rosacea program and an oral Lyme disease prophylactic, while focusing on execution and measured business development.
-
The company is driving strong adoption of its FDA-approved therapy for Demodex blepharitis, achieving broad market coverage and robust sales growth. Strategic expansion includes a new gel for ocular rosacea, with a phase II trial starting in H2 2024, and ongoing efforts to deepen physician and patient engagement.
-
Xdemvy's strong launch drove significant revenue, with broad physician adoption and a focus on expanding indications such as ocular rosacea. Growth in 2025 will be supported by new sales reps, DTC campaigns, and improved Medicare coverage, while seasonality and gross-to-net dynamics will impact quarterly results.
-
Strong growth is projected for Xdemvy in 2025, supported by broad coverage, direct-to-consumer campaigns, and a motivated sales force. Expansion into ocular rosacea represents a major new opportunity, with Phase 2 trials planned and a proven commercialization blueprint in place.
Fiscal Year 2024
-
2024 saw record Xdemvy sales, broad insurance coverage, and a major DTC campaign launch, driving strong physician and patient engagement. The pipeline advanced with new programs in ocular rosacea and Lyme disease, both with clear regulatory paths and upcoming trials.
-
Q3 2024 saw record XDEMVY sales, expanded sales force, and over 80% patient coverage. New data supports use in MGD with DB, broadening the addressable market. Strong cash position and positive outlook for continued growth into 2025.
-
Strong launch momentum with nearly 100,000 patients treated and $40M in Q2 revenue, driven by robust physician adoption and expanding coverage. Direct-to-consumer efforts and pipeline updates in MGD and Lyme disease are set to further accelerate growth.
-
XDEMVY's launch is driving strong adoption among payers and prescribers, with a growing sales force and a major DTC campaign set for Q4. Retreatment rates and expansion into new indications support a billion-dollar sales outlook, with key pipeline updates expected by year-end.
-
Q2 2024 saw $40.8M in sales, a 65% sequential increase, with strong XDEMVY adoption among ECPs and improved payer coverage. Gross-to-net discount improved to 44%, and further growth is expected as the sales force expands and DTC campaigns launch.
-
Xdemvy’s launch for Demodex blepharitis has exceeded expectations, with strong prescriber uptake, robust payer coverage, and expanding patient engagement. Growth is driven by new patient starts, with retreatments expected annually. Pipeline and international expansion offer additional upside.
-
Product sales have grown rapidly since launch, with strong physician adoption and expanding payer coverage. The addressable market is large, and upcoming DTC efforts and sales force expansion aim to accelerate growth. Pipeline programs offer additional future opportunities.
-
Xdemvy's launch for Demodex blepharitis has been highly successful, with strong sales, positive real-world efficacy, and expanding physician adoption. The company is investing in sales force growth, direct-to-consumer marketing, and advancing a robust pipeline, all supported by a strong financial position.